Metformin has been shown to reduce obesity-associated inflammation and other inflammatory responses, and it reduces serum C-reactive protein levels in women with polycystic ovary syndrome [82-86]. This evidence concerns the gene CRP and obesity due to melanocortin 4 receptor deficiency.